Reforgene named a Top 10 China medical innovation company 2021

On October 12, 2021, the "CHS 2021 Sixth China Big Health Industry Upgrade Summit" and awards dinner, hosted by the General Practice Medicine and Health Management Committee of the China Health Information and Healthcare Big Data Society and EqualOcean, and guided by the Sichuan Provincial Health Commission and the China Health Information and Healthcare Big Data Society, was grandly held in Chengdu. The "2021 China Big Health Industry Integrated Innovation List" was officially released.

Among them, the widely watched "2021 China Top 10 Medical Innovation Enterprises" was unveiled. The list aims to identify domestic hard technology enterprises representing the future direction. After intense competition and evaluation, Reforgene stood out with its rapid growth and technological innovation strength in the gene editing medicine field in recent years, and was listed among the "2021 China Top 10 Medical Innovation Enterprises".

Background

The China Big Health Industry Upgrade Summit has been successfully held for five editions. This edition, themed "Integrated Innovation, Leading Industrial Convergence", discussed topics around market environment, investment hotspots and industrial transformation in seven sub-fields including digital healthcare, AI- and computing-driven new drug R&D, primary care, payment innovation and genetic testing.

From an industry-wide perspective, driven by new technologies and new models, the big health industry is developing rapidly in a diversified ecosystem with multiple dimensions, continuously upgrading and innovating, and sub-fields are breaking down boundaries and barriers, showing a trend of convergence. As an observer and recorder deeply engaged in the big health industry, EqualOcean Health has been committed to discovering the emerging forces in the industry and helping the upgrading of the big health industry.

The evaluation criteria of this award not only took into account hard indicators such as enterprise founding time, financing rounds and operating conditions, but also considered multiple soft factors, including the prospects of the track the enterprise is in, the clarity of the project's business model, the innovativeness of the project, the obviousness of product differentiation, product or service quality, the strength of brand awareness, and business growth speed, fully understanding and accommodating the survival conditions of enterprises in the context of the COVID-19 pandemic.